FluMist QIV (AstraZeneca/Daiichi Sankyo) is a quadrivalent live-attenuated influenza vaccine containing antigens from two A strains and two B strains specified by the World Health Organization seasonally for influenza vaccination. FluMist QIV was approved for active immunization for the prevention of influenza in the US in February 2012 for subjects aged 2–49 years. FluMist QIV, branded as Fluenz Tetra in the EU, was then approved for use in subjects aged 2–18 years in December 2013 by the European Medicines Agency. Daiichi Sankyo submitted an application for regulatory approval in June 2016, and Datamonitor Healthcare estimates the Japanese launch of FluMist QIV (MEDI3250) in the 2019/20 season.
FluMist QIV (live-attenuated quadrivalent influenza vaccine; AstraZeneca/Daiichi Sankyo) is the only live-attenuated influenza vaccine
(LAIV) approved for seasonal influenza prophylaxis. Its ability to provide superior protection in infants aged 6–59 months had
previously placed the vaccine as the preferred option for children aged 2–8 years in the US (CDC, 2015).
LIST OF TABLES
6 Table 1: FluMist QIV drug profile
7 Table 2: Approval history of FluMist QIV for seasonal influenza vaccination in the US and five major EU markets
8 Table 3: Late-phase trials of FluMist QIV for seasonal influenza vaccination
9 Table 4: FluMist QIV for seasonal influenza – SWOT analysis
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.